Semaglutide
FDA ApprovedAlso known as: Ozempic, Wegovy, Rybelsus, NN9535
A GLP-1 receptor agonist FDA-approved for type 2 diabetes, obesity, cardiovascular risk reduction, and MASH. Among the most extensively studied peptides with robust Phase 3 data demonstrating significant metabolic, cardiovascular, renal, and hepatic benefits.
Research Statistics
Anchor peptide: top-tier evidence. Multiple global Phase 3 RCT programs (SUSTAIN, STEP, SELECT, FLOW, ESSENCE) with tens of thousands of participants across 40+ countries. GLP-1 receptor agonism is a textbook-level established mechanism. FDA-approved for T2D, obesity, CV risk reduction, and kidney disease.
Research Dossier
Overview
What is Semaglutide and what does the research say?
Mechanism of Action
Semaglutide is a selective GLP-1 receptor agonist with extensive Phase 3 clinical trial data supporting its mechanisms in humans.
How It Works (Simplified)
Semaglutide mimics GLP-1, a natural hormone released after eating, producing multiple therapeutic effects:
Binds to GLP-1 receptors on pancreatic beta cells, triggering glucose-dependent insulin release. Only works when blood sugar is elevated, minimizing hypoglycemia risk.
Acts on hypothalamic hunger centers, activating satiety pathways (POMC/CART) while suppressing hunger signals (NPY/AgRP). Reduces caloric intake by 20-35%.
Suppresses inappropriate glucagon secretion from alpha cells and enhances insulin sensitivity, improving overall glycemic control in type 2 diabetes.
Slows stomach emptying, prolonging satiety after meals and reducing postprandial glucose spikes. Contributes to both weight loss and glycemic benefits.
Scientific Pathways
GLP-1R Signaling Cascade (Primary Mechanism)
Semaglutide binds GLP-1R (Class B1 GPCR)
|
v
G-alpha-s activation --> Adenylyl cyclase --> cAMP increase
|
v
Protein Kinase A (PKA) activation
|
+---> Beta cells: Glucose-dependent insulin exocytosis
+---> Alpha cells: Glucagon suppression
+---> Hypothalamus: POMC/CART activation, NPY/AgRP inhibition
+---> GI tract: Delayed gastric emptyingKey Research: SUSTAIN and STEP Phase 3 programs demonstrated these mechanisms translate to clinically meaningful outcomes in over 20,000 patients. PMID:33567185
Important Limitations
- Common GI side effects: Nausea (30-45%), vomiting, diarrhea, and constipation, especially during dose titration
- Boxed warning: Thyroid C-cell tumors observed in rodents; contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2
- Gallbladder disease: Increased risk (~2.5%) associated with rapid weight loss
- Pancreatitis: Rare (~0.3%) but requires discontinuation if suspected
- Pregnancy: Contraindicated; discontinue at least 2 months before planned conception
- Weight regain: Approximately 2/3 of lost weight returns within 1 year of discontinuation (STEP 4)
- Muscle mass: ~30% of weight lost is lean mass; resistance training recommended
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial titration period. Studies show GI side effects (nausea 30-45%) are most common during dose escalation. Early appetite reduction begins. HbA1c improvements start becoming measurable. Weight loss typically 2-4% by week 4.
Continued dose escalation toward maintenance dose. GI tolerability typically improves as body adapts. Weight loss accelerates to 5-8%. Blood glucose improvements become more pronounced.
Approaching full therapeutic effect. STEP 1 showed approximately 10-12% weight loss by week 20. HbA1c reductions of 1.0-1.5% typical in diabetes trials. Blood pressure begins to improve.
Near-maximum weight loss achieved. STEP 1 showed 14.9% mean weight loss at 68 weeks. Cardiovascular markers improve. MASH patients show liver enzyme improvements.
Weight loss typically plateaus and is maintained with continued use. STEP 5 showed maintenance at 2 years. Discontinuation results in weight regain (~2/3 of lost weight within 1 year per STEP 4).
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Semaglutide product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Semaglutide with other peptides. Based on published research and mechanistic considerations.
Tesamorelin
CautionBoth affect metabolic parameters. Tesamorelin increases GH which may affect glucose homeostasis. Monitor blood glucose closely if considering combination in diabetic patients.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while semaglutide delays gastric emptying. Theoretical interaction unclear; monitor GI symptoms.
Ipamorelin
CautionGH secretagogues may affect glucose metabolism. Semaglutide treats diabetes while GH can be diabetogenic. Monitor glucose parameters if combined.
MK-677
CautionMK-677 increases GH and IGF-1, which can impair glucose tolerance. May counteract semaglutide's glycemic benefits. Monitor blood glucose closely.
Tirzepatide
AvoidDo not combine. Both are incretin-based therapies acting on overlapping pathways. Concurrent use would provide redundant GLP-1 agonism with increased risk of severe GI adverse events and hypoglycemia without proven additional benefit.
Liraglutide
AvoidDo not combine. Both are GLP-1 receptor agonists with identical mechanism of action. No clinical rationale for combination; would increase adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Semaglutide
Semaglutide Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Related Content
Tirzepatide
Metabolic · high evidence
Liraglutide
Metabolic · high evidence
What is Ozempic?
An introduction to Ozempic, the brand name for semaglutide a...
What is Rybelsus?
An introduction to Rybelsus, the oral tablet form of semaglu...
5-Amino-1MQ vs Semaglutide
View side-by-side analysis
Amycretin vs Semaglutide
View side-by-side analysis